Table 1.
Baseline characteristics of women with kidney transplant separated by contraceptive use during the follow-up period
| Characteristics | Without recorded data on contraception N = 11,193 | With recorded data on contraception N = 1957 | p value |
|---|---|---|---|
| Demographics | |||
| Age (years)ab | 33 (8) | 29 (7) | < 0.001 |
| 15–24 | 15.4 | 25.9 | < 0.001 |
| 25–29 | 13.6 | 24.0 | |
| 30–34 | 19.7 | 24.4 | |
| 35–39 | 25.9 | 16.9 | |
| 40–44 | 25.4 | 8.8 | |
| Race/ethnicity | 0.001 | ||
| Asian | 5.7 | 4.5 | |
| Black | 29.7 | 32.0 | |
| Hispanic | 20.3 | 21.7 | |
| Native American | 1.0 | 1.6 | |
| White | 43.4 | 40.3 | |
| Body mass index (kg/m2)a | 26.5 (7.4) | 25.7 (6.8) | < 0.001 |
| < 18.5 | 8.8 | 10.5 | < 0.001 |
| 18.5–25 | 39.5 | 42.0 | |
| 25.1–30 | 22.2 | 21.9 | |
| > 30 | 25.6 | 23.1 | |
| Missing | 3.9 | 2.5 | |
| Cause of ESKD | 0.005 | ||
| Cystic/hereditary | 8.6 | 8.5 | |
| Diabetes mellitus | 19.0 | 16.5 | |
| Glomerulonephritis | 28.0 | 29.8 | |
| Hypertension/large vessel disease | 12.8 | 10.7 | |
| Interstitial nephritis/pyelonephritis | 5.0 | 6.0 | |
| Malignancy | 2.8 | 3.4 | |
| Secondary glomerulonephritis/vasculitis | 15.1 | 15.5 | |
| Others | 8.7 | 9.6 | |
| Time on dialysis pre-transplant (years) | 3.0 (3.1) | 3.0 (2.9) | 0.679 |
| Neighborhood poverty levelb 0.119 | |||
| < 13.8% | 59.8 | 58.3 | |
| 13.8–20% | 18.1 | 18.6 | |
| > 20–40% | 18.8 | 20.2 | |
| > 40% | 1.4 | 1.7 | |
| Missing | 1.8 | 1.2 | |
| Geographical region < 0.001 | |||
| Midwestern | 22.8 | 26.5 | |
| Northeastern | 18.3 | 15.8 | |
| Southern | 39.4 | 36.9 | |
| Western | 19.6 | 20.8 | |
| Comorbidities | |||
| Diabetes mellitus | 18.0 | 15.3 | 0.004 |
| Hypertension/large vessel disease | 72.1 | 72.7 | 0.585 |
| Smoking | 3.0 | 3.1 | 0.862 |
| Donor type 0.069 | |||
| Living donor | 34.9 | 32.8 | |
| Deceased donor | 65.1 | 67.2 | |
| Year after transplant < 0.001 | |||
| Year 1 | 65.2 | 79.3 | |
| Year 2 | 16.9 | 13.6 | |
| Year 3 | 17.9 | 7.1 | |
| Immunosuppression at the time of transplant | |||
| Cyclosporine/tacrolimus | 94.7 | 94.9 | 0.780 |
| Mycophenolate | 90.0 | 90.3 | 0.730 |
| Sirolimus | 7.0 | 6.2 | 0.209 |
| Steroids/prednisone | 94.0 | 94.0 | 0.989 |
| GFR at 6 months after transplantation (ml/min/1.73 m2)a | 62.7 (25.0) | 63.6 (22.5) | 0.118 |
| ≥ 60 | 48.6 | 47.4 | 0.094 |
| < 60 | 50.5 | 52.1 | |
| Missing | 0.9 | 0.5 | |
aReported in mean (standard deviation); all others are reported as percentages of person-years. ESKD end stage kidney disease
bValues associated with women’s first eligible year for study